191 related articles for article (PubMed ID: 10637480)
1. The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia.
So CW; Dong S; So CK; Cheng GX; Huang QH; Chen SJ; Chan LC
Leukemia; 2000 Jan; 14(1):77-83. PubMed ID: 10637480
[TBL] [Abstract][Full Text] [Related]
2. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
[TBL] [Abstract][Full Text] [Related]
3. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways.
Dong S; Tweardy DJ
Blood; 2002 Apr; 99(8):2637-46. PubMed ID: 11929748
[TBL] [Abstract][Full Text] [Related]
4. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
[TBL] [Abstract][Full Text] [Related]
5. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
[TBL] [Abstract][Full Text] [Related]
6. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.
Cheng GX; Zhu XH; Men XQ; Wang L; Huang QH; Jin XL; Xiong SM; Zhu J; Guo WM; Chen JQ; Xu SF; So E; Chan LC; Waxman S; Zelent A; Chen GQ; Dong S; Liu JX; Chen SJ
Proc Natl Acad Sci U S A; 1999 May; 96(11):6318-23. PubMed ID: 10339585
[TBL] [Abstract][Full Text] [Related]
7. The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties.
Redner RL; Chen JD; Rush EA; Li H; Pollock SL
Blood; 2000 Apr; 95(8):2683-90. PubMed ID: 10753851
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.
Imaizumi M; Suzuki H; Yoshinari M; Sato A; Saito T; Sugawara A; Tsuchiya S; Hatae Y; Fujimoto T; Kakizuka A; Konno T; Iinuma K
Blood; 1998 Jul; 92(2):374-82. PubMed ID: 9657734
[TBL] [Abstract][Full Text] [Related]
9. Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein.
Jansen JH; Löwenberg B
Semin Hematol; 2001 Jan; 38(1):37-41. PubMed ID: 11172538
[TBL] [Abstract][Full Text] [Related]
10. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
11. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia.
Hong SH; David G; Wong CW; Dejean A; Privalsky ML
Proc Natl Acad Sci U S A; 1997 Aug; 94(17):9028-33. PubMed ID: 9256429
[TBL] [Abstract][Full Text] [Related]
12. Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex.
Puccetti E; Sennewald B; Fosca-Ferrara F; Boehrer S; Bianchini A; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
Hematol J; 2001; 2(6):385-92. PubMed ID: 11920278
[TBL] [Abstract][Full Text] [Related]
13. The molecular biology of acute promyelocytic leukemia.
Slack JL; Gallagher RE
Cancer Treat Res; 1999; 99():75-124. PubMed ID: 9891864
[TBL] [Abstract][Full Text] [Related]
14. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
16. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
[TBL] [Abstract][Full Text] [Related]
17. Activation of
Zhang F; Zhu YL; Deng WL; Zhu J; Zhang J
J Leukoc Biol; 2017 Mar; 101(3):655-664. PubMed ID: 27605212
[TBL] [Abstract][Full Text] [Related]
18. Essential role for the dimerization domain of NuMA-RARalpha in its oncogenic activities and localization to NuMA sites within the nucleus.
Dong S; Qiu J; Stenoien DL; Brinkley WR; Mancini MA; Tweardy DJ
Oncogene; 2003 Feb; 22(6):858-68. PubMed ID: 12584566
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia.
Hummel JL; Wells RA; Dubé ID; Licht JD; Kamel-Reid S
Oncogene; 1999 Jan; 18(3):633-41. PubMed ID: 9989813
[TBL] [Abstract][Full Text] [Related]
20. Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia.
Takayama N; Kizaki M; Hida T; Kinjo K; Ikeda Y
Exp Hematol; 2001 Jul; 29(7):864-72. PubMed ID: 11438209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]